AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) shares saw strong trading volume on Wednesday . 16,254,968 shares traded hands during mid-day trading, an increase of 851% from the previous session’s volume of 1,709,891 shares.The stock last traded at $2.41 and had previously closed at $2.41.
Several equities analysts recently issued reports on the company. Maxim Group set a $4.00 price target on AEterna Zentaris and gave the company a “buy” rating in a research report on Wednesday. Zacks Investment Research upgraded AEterna Zentaris from a “hold” rating to a “buy” rating and set a $2.50 target price on the stock in a research report on Tuesday. Finally, HC Wainwright set a $3.00 target price on AEterna Zentaris and gave the stock a “buy” rating in a research report on Wednesday, November 29th.
The company has a market cap of $37.00, a PE ratio of -1.26 and a beta of 0.87.
AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.03). AEterna Zentaris had a negative return on equity of 732.74% and a negative net margin of 2,338.61%. equities analysts forecast that AEterna Zentaris Inc. will post -1.5 earnings per share for the current year.
A hedge fund recently raised its stake in AEterna Zentaris stock. JPMorgan Chase & Co. increased its position in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,800 shares of the biopharmaceutical company’s stock after acquiring an additional 46,500 shares during the period. JPMorgan Chase & Co. owned approximately 0.35% of AEterna Zentaris worth $120,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.01% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “AEterna Zentaris (AEZS) Sees Large Volume Increase” was first posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2018/01/19/aeterna-zentaris-aezs-sees-large-volume-increase-2.html.
About AEterna Zentaris
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.